MGTX - MeiraGTx Holdings plc
About MeiraGTx Holdings plc (https://www.meiragtx.com)
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Alexandria Forbes | Chief Executive Officer, President & Director | 1965 | $2,506,506 USD |
| Richard Brian Giroux | Chief Operating Officer & Chief Financial Officer | 1974 | $2,325,000 USD |
| Stuart Naylor | Chief Development Officer | 1963 | $1,101,165 USD |
| Robert K. Zeldin | Chief Medical Officer | 1963 | $1,064,423 USD |
| Christine Elise Sheehy | Senior Vice President of Global Integration | 1968 | – |
| David Rubinstein | Senior Vice President of Business Development | – | – |
| Michel Michaelides | Head of Clinical Ophthalmology | – | – |
| Robert J. Wollin | General Counsel & Secretary | 1976 | – |
| Tassos Georgiadis | Senior Vice President of Discovery & Preclinical Development | – | – |
| Tim Randall | Senior Vice President of Risk & Internal Controls | – | – |